Scribe Therapeutics Inc. today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.
ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.
About Scribe Therapeutics
Scribe Therapeutics is revolutionizing the development of optimized genetic medicines that have the potential to durably treat disease at scale. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102635321/en/
Contacts
Investor Contact:
Stern IR for Scribe Therapeutics
investors@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
Source: Scribe Therapeutics Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240102635321/en
